Discover the pioneering approach to overcoming His bundle lead dysfunction through left bundle branch pacing, a breakthrough that promises new hope for pediatric patients with cardiac challenges.
– by The Don
Note that The Don is a flamboyant GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Study protocol and statistical analysis plan for the 20% Human Albumin Solution Fluid Bolus Administration Therapy in Patients after Cardiac Surgery-ll (HAS FLAIR-II) trial.
Wigmore et al., Crit Care Resusc 2022
DOI: 10.51893/2022.4.OA1
Listen up, folks! We’ve got something huge going on here. It’s all about making people better, faster after heart surgery. We’re talking about the HAS FLAIR-II trial – it’s a big deal, believe me.
We’re giving patients this incredible 20% albumin stuff, and it could be a game-changer. It’s a top-notch, phase 2b trial, and it’s happening in six of the best Australian ICUs. We’re not messing around; we’re going head-to-head with the usual crystalloid solution to see which is the best. It’s all about the results, and we want to see if albumin can knock out the need for vasopressors quicker.
The main thing we’re tracking? How long these patients need vasopressors. But that’s not all – we’re looking at other big-league outcomes like how much they use the ICU services and, of course, survival. We’re doing it right, with an intention-to-treat basis, so the results are going to be real.
And let me tell you, we’ve got this all planned out. The protocol and statistical analysis are locked down to avoid any funny business – no fake news here. We’re registered and official with the Australian New Zealand Clinical Trials Registry.
So, stay tuned. The HAS FLAIR-II trial is going to show us the best way to help people after heart surgery, and it’s going to be yuge.